Population coverage by HLA class-I restricted cytotoxic T-lymphocyte epitopes

Immunogenetics

Volumn 52, Issue 3-4, 2001, Pages 165-173

  Longmate, Jeffrey ^a   York, Joanne ^a   La Rosa, Corinna ^a   Krishnan, Radhika ^a   Zhang, Ming ^a   Senitzer, David ^a   Diamond, Don J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Cytotoxic T lymphocyte; Epitope; HLA class I; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; EPITOPE; HLA ANTIGEN CLASS 1; SYNTHETIC PEPTIDE;

ALLELE; ARTICLE; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; ETHNIC GROUP; GENE FREQUENCY; HLA SYSTEM; HUMAN; HUMAN CELL; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; NATURAL KILLER CELL; PRIORITY JOURNAL; VACCINATION;

ALLELES; CONTINENTAL POPULATION GROUPS; CROSS REACTIONS; CYTOMEGALOVIRUS; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; ETHNIC GROUPS; GENE FREQUENCY; HAPLOTYPES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOLOGIC MEMORY; SEROLOGY; T-LYMPHOCYTES, CYTOTOXIC;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5;

EID: 0035135665     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510000271     Document Type: Article

References (42)

1. A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets
2. HLA-A2 subtypes are functionally distinct in peptide binding and presentation
3. Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis
4. Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells
5. Identification of potential CTL epitopes of tumor-associated antigen MAGE-1 for five common HLA-A alleles
6. Dissecting the multifactorial causes of immunodominance in class I-restricted T cell responses to viruses
7. Development of a candidate HLA A *0201 restricted peptide-based vaccine against human cytomegalovirus infection
8. Functional heterogeneity of HLA-A *02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones
9. HLA A/B and DRB1/DQB1 allele-level haplotype frequencies
10. Two complementary methods for predicting peptides binding major histocompatibility complex molecules
11. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice
12. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes
13. High frequency of cytomegalovirus-specific cytotoxic T-effector cells in HLA-A*0201-positive subjects during multiple viral coinfections
14. Methods to study peptides associated with MHC class I molecules
15. Target structures of the CD8(+)-T-cell response to human cytomegalovirus: The 72-kilodalton major immediate-early protein revisited
16. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: Influence of peptide conformation and TCR-peptide interaction
17. Development of an in vitro stimulation protocol to measure CMV specific CTL activity using HLA-restricted CTL epitopes
18. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors
19. Human cytomegalovirus matrix protein PP150 is efficiently presented as one of target antigens for cytotoxic T lymphocyte recognition
20. Immunization with the HBV core 18-27 epitope elicits CTL responses in humans expressing different HLA-A2 supertype molecules
21. HLA class I region sequences, 1998
22. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes
23. HLA gene and haplotype frequencies in the North American population: The National Marrow Donor Program Donor Registry
24. Pools of lipidated HTL-CTL constructs prime for multiple HBV and HCV CTL epitope responses
25. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains
26. Peptides naturally presented by MHC class I molecules
27. A pentapeptide as minimal antigenic determinant for MHC class I-restricted T lymphocytes
28. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
29. Minimal phenotype panels: A method for achieving maximum population coverage with a minimum of HLA antigens
30. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: Implications for unrelated bone marrow donor selection
31. HLA supertypes and supermotifs: A functional perspective on HLA polymorphism
32. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism
33. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes
34. Specificity and degeneracy in peptide binding to HLA-B7-like class I molecules
35. Molecular typing for HLA class I using ARMS-PCR: Further developments following the 12th International Histocompatibility Workshop
36. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells
37. Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans
38. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
39. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma
40. The memory cytotoxic T-lymphocyte (CTL) response to human cytomegalovirus infection contains individual peptide-specific CTL clones that have undergone extensive expansion in vivo
41. In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides
42. The human CTL response to cytomegalovirus is dominanted by structural protein pp65: Frequency, specificity, and T cell receptor usage of pp65-specific CTL